Fundraising Fox
/Companies
Sign in

Inflammatix, Inc.

Burlingame, US · Founded 2016 · Delaware corporation · 72 employees on LinkedIn · 10 known investors

Find your way into Inflammatix, Inc.

2,692 people in our graph can introduce you to the Inflammatix, Inc. team.

Sign up to see every warm intro you have to Inflammatix, Inc.

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Inflammatix, Inc. team. We find them
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Inflammatix develops host-response-based molecular diagnostics tests to identify acute infections and sepsis in emergency and critical care settings. The company's diagnostic platform serves healthcare providers treating acutely ill patients, with applications extending to emerging infectious diseases, autoimmune conditions, and transplant rejection.

AI & Machine LearningBiotechHealthtechMedical Devices

Founders & leadership

Inflammatix, Inc. was founded in 2016 by Tim Sweeney and Purvesh Khatri.

TSTim Sweeney
Tim SweeneyCo-Founder and CEOTim Sweeney is a physician who transitioned to building diagnostic products, motivated by observing clinicians make high-stakes decisions with incomplete information in acute care settings. He is co-founder and CEO of Inflammatix, which develops host-response molecular diagnostics for identifying acute infections and sepsis in emergency and critical care.
PKPurvesh Khatri
Purvesh KhatriFounderPurvesh Khatri is co-founder and chief scientist at Inflammatix, which develops molecular diagnostic tests for acute infections and sepsis. His background includes work in translational medicine, biomarker discovery, and computational biology.
JRJONATHAN ROMANOWSKY
JONATHAN ROMANOWSKYCo-Founder & Board MemberJonathan Romanowsky holds an MBA and has background in strategic consulting and healthcare software. He serves as Executive Officer at Inflammatix, which develops molecular diagnostic tests for identifying acute infections and sepsis in clinical settings.
TS
Timothy SweeneyFounder

Board

KB
KENNETH BAHKBoard director
MR
MICHAEL RUBINBoard director
DP
DAVID PERSINGBoard director
ST
STEVEN TABLAKBoard director

Investors · 10

Northpond Ventures✓ confirmed by Inflammatix, Inc.Bethesda · $100K – $5M

How we know: the company's own site · inflammatix.com · Not right? Tell us

Initiate Venture Partnerslisted by Initiate Venture PartnersPark City · $500K – $2M
Marram Ventureslisted by Marram VenturesSaugatuck · $3M

How we know: Marram Ventures's portfolio page · Not right? Tell us

OSF Ventureslisted by OSF VenturesPeoria
StartXlisted by StartXStanford · $10K – $1M

How we know: StartX's portfolio page · Not right? Tell us

DFJinferredSan Mateovia Justin Kao · board

How we know: board seat on SEC Form D · Not right? Tell us

Also in the syndicate · 3

D1 Capital PartnersleadGrey Sky Venture PartnersThink.Health Ventures

Reported raises · per SEC filings

Form D private placements

$134.5M disclosed across 2 of 3 rounds · 2020–2024

▶$102.4MraisedMar 2021 · 8 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • MICHAEL RUBINDirector
  • JUSTIN KAODirector
  • KENNETH BAHKDirector
  • TIMOTHY SWEENEYExecutive Officer, Director
  • STEVEN TABLAKDirector
  • DAVID PERSINGDirector
Offering amount
$102.4M
Amount sold
$102.4M
First sale
Mar 2021
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$32.1MraisedFeb 2020 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • TIMOTHY SWEENEYExecutive Officer, Director
  • JONATHAN ROMANOWSKYExecutive Officer
  • KENNETH BAHKDirector
  • DAVID PERSINGDirector
  • STEVEN TABLAKDirector
  • MICHAEL RUBINDirector
Offering amount
$32.1M
Amount sold
$32.1M
First sale
Jan 2020
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 1

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies working in the same space as Inflammatix, Inc..

Non-dilutive funding · 4 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase I2023$299.8K
National Institutes of Health (NIH)National Institutes of HealthPhase II2021$1.7M
National Institutes of Health (NIH)National Institutes of HealthPhase I2021$251.4K
Defense Advanced Research Projects Agency (DARPA)Defense Advanced Research Projects AgencyPhase II2017$999.9K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Inflammatix Secures $57 Million to Advance Novel Diagnostic for Patients with Suspected Infections or Sepsisprnewswire.com · Sep 2024Inflammatix Secures $102 Million in Series D Financing Led by D1 Capital Partners to Commercialize Novel Host Response Diagnostics - Inflammatixinflammatix.com · Mar 2021Inflammatix Announces $32 Million in Series C Funding - Inflammatixinflammatix.com · Jan 2020

Frequently asked questions

What does Inflammatix, Inc. do?
Inflammatix develops host-response-based molecular diagnostics tests to identify acute infections and sepsis in emergency and critical care settings. The company's diagnostic platform serves healthcare providers treating acutely ill patients, with applications extending to emerging infectious diseases, autoimmune conditions, and transplant rejection.
Who founded Inflammatix, Inc.?
Inflammatix, Inc. was founded by Tim Sweeney, Purvesh Khatri in 2016.
Who are Inflammatix, Inc.'s investors?
Inflammatix, Inc.'s investors include Khosla Ventures, Northpond Ventures, Initiate Venture Partners, Marram Ventures, OSF Ventures, StartX, DFJ.
How much funding has Inflammatix, Inc. raised?
Inflammatix, Inc. has disclosed $134.5M raised across 2 of its 3 known rounds.
Where is Inflammatix, Inc. headquartered?
Inflammatix, Inc. is headquartered in Burlingame, US.